https://www.cytodyn.com/newsroom/press-releas...e-2-clover
VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced that updated clinical data from its ongoing Phase 2 CLOVER study (ClinicalTrials.gov Identifier: NCT06699836), evaluating leronlimab in combination with trifluridine and tipiracil (“TAS-102”) plus bevacizumab in patients with previously treated mCRC, will be presented at the ESMO Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.
Details of the poster presentation are as follows:
Abstract title:
Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study
Presenter:
Benjamin Weinberg, M.D., Associate Professor at Georgetown University
Date and Time:
Sunday, October 25, 2026, 12:00-12:45 p.m. CET (local time)
Poster ID:
820P
Location: Poster Area, Hall 5, IFEMA Madrid
“We are excited to present updated findings from the CLOVER study at ESMO and share additional clinical and translational insights from our metastatic colorectal cancer program,” said Jacob P. Lalezari, M.D., Chief Executive Officer of CytoDyn. “These data will contribute to our understanding of CCR5 biology in colorectal cancer and help inform the continued development of leronlimab in combination with established therapies for patients with difficult-to-treat disease.”
A copy of the poster will be made available on CytoDyn’s website under the Publications & Posters section, shortly after the presentation date.
About the European Society for Medical Oncology (ESMO) Congress 2026
The ESMO Congress 2026, taking place October 23–27, 2026, in Madrid, Spain, is a leading global oncology meeting bringing together clinicians, researchers, patient advocates, journalists and healthcare industry representatives from around the world. The Congress provides a global platform for advances in oncology research, clinical practice and patient care, featuring new scientific data, educational programming, networking opportunities and innovation across the oncology community. For more information, visit esmo.org.